Glycopeptide use at four university hospitals in southern Germany

被引:9
作者
Kern, WV
de With, K
Trautmann, M
Kern, P
Gonnermann, C
机构
[1] Univ Hosp, Div Infect Dis, Dept Med 2, D-79106 Freiburg, Germany
[2] Univ Hosp, Sect Infect Dis & Clin Immunol, D-89070 Ulm, Germany
[3] Med Ctr, D-89070 Ulm, Germany
[4] Univ Hosp, Sect Hosp Hyg, D-89070 Ulm, Germany
[5] Univ Hosp, Hosp Pharm, VZM, D-89070 Ulm, Germany
关键词
D O I
10.1007/s15010-002-2161-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Excessive use of glycopeptide antibiotics may enhance the risk of glycopeptide resistance among enterococci and staphylococci, but there is Little data on the use of these antibiotics in German hospitals. Methods: Hospital pharmacy records for the years 1992 to 1994 were evaluated. The number of defined daily doses (DDD) per 100 patient days was calculated to compare glycopeptide use between four state university hospitals. At one of the hospitals with comparatively tow glycopeptide usage but an active antimicrobial management program, data were prospectively evaluated for 1995 to 2000 to assess the variation of glycopeptide use over time. Results: The 3-year averages in glycopeptide use for the four hospitals ranged between 1.03 and 3.14 DDD/100 patient days. In at four hospitals, glycopeptide use was higher in the medical service (range, 1.59-7.26) than in the surgical service (range, 0.66-4.39). Active antimicrobial management in one of the hospitals was associated with containment of glycopeptide consumption in the medical and surgical service at < 1.5 DDD/100 patient days in the Last 3 years. Conclusion: Glycopeptide use differs considerably at tertiary care hospitals in southern Germany, but use of < 1.5 DDD/100 patient days in both surgical as well as medical tertiary care hospital departments appears achievable.
引用
收藏
页码:262 / 266
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 1995, MMWR Recomm Rep, V44, P1
[2]   Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy [J].
Bassetti, M ;
Di Biagio, A ;
Rebesco, B ;
Cenderello, G ;
Amalfitano, ME ;
Bassetti, D .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (03) :295-299
[3]   TEICOPLANIN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL [J].
CAMPOLIRICHARDS, DM ;
BROGDEN, RN ;
FAULDS, D .
DRUGS, 1990, 40 (03) :449-486
[4]   Parenteral antibiotic use in acute-care hospitals: A standardized analysis of fourteen institutions [J].
Carling, PC ;
Fung, T ;
Coldiron, JS .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) :1189-1196
[5]  
CHEUNG RPF, 1986, PHARMACOTHERAPY, V6, P153
[6]   THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY [J].
ENA, J ;
DICK, RW ;
JONES, RN ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05) :598-602
[7]   Vancomycin use in a university medical center: Effect of a vancomycin continuation form [J].
Evans, ME ;
Millheim, ET ;
Rapp, RP .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) :417-420
[8]   Evaluation of vancomycin use in a large university-affiliated hospital in eastern France in 1999 [J].
Floret, N ;
Thouverez, M ;
Thalamy, B ;
Estavoyer, JM ;
Talon, D .
PHARMACY WORLD & SCIENCE, 2001, 23 (03) :93-97
[9]   Determinants of vancomycin use in adult intensive care units in 41 United States hospitals [J].
Fridkin, SK ;
Edwards, JR ;
Pichette, SC ;
Pryor, ER ;
McGowan, JE ;
Tenover, FC ;
Culver, DH ;
Gaynes, RP .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1119-1125
[10]   Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2 [J].
Fridkin, SK ;
Steward, CD ;
Edwards, JR ;
Pryor, ER ;
McGowan, JE ;
Archibald, LK ;
Gaynes, RP ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :245-252